Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362440 · ClinicalTrials.gov registry record · Phase 2
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00362440 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 9 participants.
The verdict
NCT00362440, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and leptin (a natural hormone produced by your fat cells). Our hope is that they will improve sugar and fat metabolism and positively affect the body fat changes you have noticed while taking HAART.
Interventions
- DRUG Placebo
- DRUG Leptin
- DRUG Pioglitazone or metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362440
The ClinicalTrials.gov registry entry for NCT00362440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00362440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00362440 about?
NCT00362440 is a clinical study titled "Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome". The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and leptin (a natural hormone produced by your fat cells). Our hope is that...
What is the current status of trial NCT00362440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2006-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00362440?
The interventions under investigation include: Placebo (DRUG), Leptin (DRUG), Pioglitazone or metformin (DRUG).
Who is sponsoring clinical trial NCT00362440?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.